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Vaccinia virus (VACV) is a double-strand DNA virus belonging to Orthopoxvirus genus of 
the family Poxviridae. After entry VACV replicates entirely in cytoplasm of the host cell, 
using virally-encoded DNA replication and transcription machinery. Nevertheless, a recent 
siRNA screen revealed that the nuclear export protein nucleoporin 62 (NUP62) plays a role in 
VACV morphogenesis, suggesting VACV requires the host cell nucleus for virus replication. 
In order to investigate this further we analysed the effect of two chemical inhibitors of 
nuclear-cytoplasmic transport, leptomycin B and 335, on the replication of VACV in HeLa 
and A549 cells. No significant difference was detected in viral titre when nuclear export was 
inhibited with drug treatment, as this resulted in only a three-fold reduction in virus titre. In 
contrast, both drugs reduced the yield of influenza virus (which is known to be dependent on 
nuclear-cytoplasmic transport) by 200 fold. These results indicate that VACV is able to 
replicate to near normal titres in cells with reduced nuclear export. A siRNA interference 
study also uncovered MAST3 (microtubule-associated serine/threonine kinase 3) as a putative 
pro-viral cellular protein. MAST3 contains a serine/threonine kinase domain and a PDZ 
protein interaction domain. The present study demonstrated a statistically significant 
reduction of VACV replication in HeLa cells in the presence of MAST3-targeted siRNA. This 








Most viruses including influenza virus require the nucleus of their host cell, therefore virus 
replication can be blocked by inhibiting nuclear-cytoplasmic transport via disruption of the 
nucleus pore structure. However, one exception is the poxvirus family, a family of DNA 
viruses whose life cycle occurs entirely in the area called the virus factory in cytoplasm. Thus 
no drug targeting to nuclear-cytoplasmic transport is supposed to affect poxviruses. However, 
a recent poxvirus study suggested that virus yield can be reduced by inhibiting virus 
maturation using the siRNA knockdown technique to remove one element of the nucleus pore 
complex, nucleoporin 62. In order to investigate this further, we established a nuclear-
cytoplasmic trafficking interfering experiment in which HeLa cells and A549 cells were 
treated with two drugs of nuclear -cytoplasmic transport, Leptomycin B and 335, following 
infection of Vaccinia virus (VACV), a family member of poxvirus. Drug treatment resulting 
in only a non-significant three-fold reduction in VACV virus growth, suggesting that VACV 
is able to replicate to near normal titres in cells with reduced nuclear-cytoplasmic transport. In 
comparison, in a parallel study influenza virus replication was reduced by 200 fold. In 
addition to nuclear-cytoplasmic transport, a siRNA interference study also uncovered a 
cellular protein MAST3 (microtubule-associated serine/threonine kinase 3) that may take part 
in virus replication. MAST3 is a cellular signaling messenger MAST3 contains a 
serine/threonine kinase domain for catalytic function and a PDZ protein interaction domain as 
a binding site. The present study demonstrated a statistically significant reduction of VACV 
replication in HeLa cells in the presence of MAST3-targeted siRNA. This work provides new 
















VARV-Variola virus  
VACV- Vaccinia virus  
IMV - Intracellular mature virus 
MTOC - microtubule organizing centre  
TGN - trans-Golgi network  
IEV - intracellular enveloped virus  
CEV - cell-associated enveloped virus  
EEV - extracellular enveloped virus  
NF-κB - Nuclear factor kappa B  
MAP- microtubule-associated protein 
IκBα - inhibitor of kappa B alpha  
IL - interleukin  
TNF - tumor necrosis factor  
TLRs - Toll-like receptors 
MyD88 - myeloid differentiation factor 88  
TRAF6 - TNF receptor-associated factor 6  
IRAK2 - IL-1 receptor-associated kinase 2  
IKK - kappa B kinase  
siRNA - interfering RNA  
NUPs - nucleoporins  
NLS - nuclear localization signal  
NES - nuclear export signal 
CRM1- chromosome region maintenance 1, also known as exportin 1 
NXF1 - TIP associated protein TAP 
RanGAP1 - GTPase-activating protein1 
RCC1 - Regulator of chromosome condensation 1 
HRV - Human rhinovirus   
PV - polivovirus  
EMCV - Encephalomyocarditis virus  
ISRE - interferon stimulated response elements  
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ORF6 - open reading frame 6  
SARSCoV - severe acute respiratory syndrome coronavirus  
AdVs - Adenoviruses  
E4orf6 - open reading frame 6  


















































Poxviridae is a family of large, double stranded DNA viruses with a broad range of hosts 
including vertebrates and arthropods. There are two subfamilies, Chordopoxvirinae and 
Entomopoxvirinae, which including 28 genera and 69 species. The 10 genera in the 
Chordopoxvirinae subfamily contain species that infect mammals, and include the genera 
Orthopoxvirus, Parapoxvirus, Avipoxivrus, Capripoxvirus, Leporipoxvirus, Suipoxvirus, 
Molluscipoxvirus and Yatapoxivrus genus. Entomopoxvirinae is a subfamily of poxviral 
species infecting insects, including Alphaentomopoxvrius genus, Betaentomopoxvrius genus 
and Gammaentomopoxvirus genus (Bernard N Fields; David M Knipe (David Mahan) 2001). 
1.2 Vaccinia virus 
 
Vaccinia virus (VACV) belongs to the Orthopoxvirus genus along with Variola virus (the 
causative agent of smallpox), Monkeypox virus and Ectromelia virus (Bernard N Fields; 
David M Knipe (David Mahan) 2001). VACV encodes a 190kbp linear genome compacted in 
the core of the virus (Gubser, Hue et al. 2004). The ellipsoidal shaped virion mature virion has 
major and minor axes measuring 320 to 380nm and 260 to 340nm respectively (Malkin, 
McPherson et al. 2003). In the 19th and 20th centuries, VACV was widely used as a vaccine 
against smallpox, resulting in the complete eradication of this disease. Today studies into 
VACV continue as it is an excellent model to look at virus-host interactions, for example it 
interferes the innate immune system of the host through a wide range of novel 
immunomodulatory virus proteins (Smith, Benfield et al. 2013) and modulates the host cell 
cytoskeleton (Leite and Way 2015) VACV and attenuated strains such as modified Vaccinia 
virus Ankara (MVA) are also being developed as vaccine vectors against a variety of human 
and animal diseases including HIV, malaria, tuberculosis and cancer, and as an oncolytic 
agents (Gomez, Najera et al. 2011).  
1.3 Poxvirus disease and symptoms 
 
Smallpox was the most serious poxvirus disease in humans, caused by Variola virus (VARV). 
It was spread by inhalational exposure of oral, nasal or pharyngeal droplets that contained the 
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virus and initially caused influenza like symptoms such as fever of at least 38.3°C, muscle 
pain, malaise, headache and prostration. After 10-14 days incubation the classic poxvirus rash 
would appear on the face, all four limbs, mucous membranes of the mouth, tongue, palate and 
throat. When visible lesions were first observed, the temperature fell to near normal, and the 
lesions rapidly enlarged and ruptured, developing from macules to papules and eventually 
pustules that dried up and crusted over by 14 to 16 days if the patient survived. By day 16-20, 
scabs would form over all the lesions and flake off, leaving depigmented scars (Bernard N 
Fields; David M Knipe (David Mahan) 2001). Smallpox was declared eradicated in 1980 due 
to a highly successful worldwide vaccination programme using VACV.  
VACV causes a much milder disease than VARV, characterised by rash, fever, headache, and 
muscle pain. The virus replicates at the site of inoculation, forming local erythematous 
maculopapules. These maculopapules then vesiculate, scar and heal over by 10-14 days 
(Bernard N Fields; David M Knipe (David Mahan) 2001). Poxviruses are cross-protective 
within genus, consequently prior infection with VACV protects against infection with VARV 
and therefore smallpox. This was the basis of the smallpox vaccination programme. 
1.4  Virus life cycle 
 
During the VACV lifecycle four different types of VACV virions are produced within the 
cytoplasm of the cell (Figure 1.1). Intracellular mature virions (IMV) surrounded by a single 
membrane are the first and most numerous virion produced. The vast majority of IMVs 
remain within the cytoplasm in viral factories until cell lysis, however a small percentage of 
them are transported to sites near the microtubule organizing centre (MTOC) where they 
obtain a double-layer of membrane that is derived from either the trans-Golgi network (TGN) 
(Smith and Law 2004) or early endosomes (Tooze, Hollinshead et al. 1993, van Eijl, 
Hollinshead et al. 2000), forming intracellular enveloped virus (IEV) with a total of three 
membranes. IEVs then travel to the cell periphery using microtubules (Ward and Moss 2001, 
Risco, Rodriguez et al. 2002). Once IEV approaches the cell surface the outer membrane of 
IEV fuses with the plasma membrane, which exposes the enveloped virion on the cell surface; 
the virion is now known as a cell-associated enveloped virus (CEV) and has a total of two 
membranes. On the cell surface, CEVs can be propelled towards uninfected cells by actin tails 
forming beneath the plasma membrane (Payne 1980, Law, Hollinshead et al. 2002). When 
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CEVs are released from the cell they are known as extracellular enveloped virus (EEV). They 
mediate longer-range dissemination in vitro and in vivo. Therefore CEV and EEV forms are 
crucial for virus dissemination (Roberts and Smith 2008).   
 
Figure 1.1 Morphogenesis of VACV. After maturing in the virus factory, the IMV 
either remains in the viral factory until cell lysis or are transported via microtubules to 
a site near the MTOC to form IEV by double wrapping. IEV particles are transported 
to the surface via microtubules where the outer membrane fuses with the cell 
membrane to expose the CEV on the cell surface. CEVs either induce the 
polymerisation of actin beneath he plasma membrane or are released as EEVs. 
 
The IMV, surrounded by one membrane, enters cells via fusion of this virus membrane with 
the plasma membrane, or via macropinocytosis followed by fusion with the endosomal 
membrane. Fusion of the virus membrane with the cell membrane is catalyzed by virus 
proteins from enveloped viruses. A complex of 11 to 12 non-glycosylated, transmembrane 
viral proteins function in this unique fusion machinery. However CEV and EEV are 
surrounded by two membranes, not one, and therefore raise a topological difficulty to explain 
their entry. This question was answered by the discovery of a non-fusogenic mechanism 
mediated by specific molecules on the surface of the cell and virus which disrupted the EEV 
outer membrane and exposed the IMV particle within to the plasma membrane. The 
consequent process of entry then resembles the free IMV particle. In addition, the CEV/EEV 
outer membrane remains over the IMV particle as a shroud and protect the IMV particle from 
antibody. Once a virion has gained entry into a cell, the VACV lifecycle is initiated and 
protects, translation and DNA synthesis occur. 
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1.5 Virus gene transcription and translation 
 
VACV transcription and translation occurs in the cytoplasm. The core of the infecting virion 
enters the cytoplasm and is transported on microtubules to a perinuclear location, known as 
the viral factory. The core of the poxvirion contains a complete viral transcriptional system 
including capping enzyme, poly A polymerase, early transcription initiation factor and early 
transcription termination factor (Condit, Moussatche et al. 2006). The virus genome is 
transcribed into early mRNAs by the virus-associated DNA-dependent RNA polymerase; 
these early mRNAs encode proteins such as the viral DNA polymerase, and enzymes to 
increase the size of the nucleoside pool.  
After the onset of early protein expression the DNA genome is released for replication. The 
pattern of transcription changes to intermediate genes. Then late genes once the replication of 
virus DNA is finished. Generally, late genes encode structural proteins, additional virulence 
factors, or enzymes that are packaged into new virions to aid early gene transcription in the 
next cycle of infection. (Broyles 2003).  
1.6 Host cell interaction during VACV morphogenesis.  	
 
Poxviruses undertake a complex replication cycle within the cell cytoplasm, involving many 
virus-host interactions. Two examples are the interaction between the virus and cellular 
cytoskeleton, and between the virus and NF-B pathways. 
Microtubules and actin are fundamental structures of the cytoskeleton and both facilitate the 
transport of the poxvirion at different points in its cytoplasmic life cycle. When infectious 
virus enters the cell, VACV viral protein A10L and L4R play a role of MAP-like 
(microtubule-associated protein) properties and mediate interactions of the invading viral core 
with microtubule, which facilitates virus achieve a peri-nuclear localization. Later in the life 
cycle newly assembled IMV particles are transported from factories to near MTOC 
(microtubule organizing center) via microtubules. Subsequently, the IEV moves to the cell 
surface to form CEV again using microtubules. The CEV proteins A36R stimulates the 
formation of actin tail, which aids their particles cell-to-cell spreading.  
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Nuclear factor kappa B (NF-κB) is an important transcription factor for the expression of 
many pro-inflammatory molecules. NF-κB is retained in the cytosol of resting cells bound to 
the inhibitor of kappa B alpha (IκBα). Phosphorylation, ubiquitination and degradation of 
IκBα releases NF-κB which then translocates into nucleus to activate immune response genes. 
Upstream of IκBα there are different signaling pathways, such as the interleukin (IL)-1 
receptor with IL-1β, tumor necrosis factor (TNF) receptor with TNF-α, or Toll-like receptors 
(TLRs) with their respective-ligands. These pathways are widely hijacked by VACV virus 
proteins, including A46, A52, N1, B14, M2, K1 and E3, resulting in inhibition of NF-κB 
immune response in vivo (Ember, Ren et al. 2012). Protein A46 contains a Toll-like-
interleukin-1 resistance (TIR or IL-1) domain which targets the host TIR adaptor on TRIF, 
myeloid differentiation factor 88 (MyD88) and Toll-like receptors. Protein A52 targets both 
TNF receptor-associated factor 6 (TRAF6) and IL-1 receptor-associated kinase 2 (IRAK2) 
and inhibits NF-κB activation downstream of TLRs and the IL-1 receptor. Protein B14 binds 
to inhibitor of kappa B kinase (IKK)β, upstream of IκBα and thereby inhibits consequential 
phosphorylation of IκBα. Viral protein M2 directly inhibits NF-κB pathway by preventing 
p65 nuclear translocation and also interferes with MEK-directed phosphorylation of ERK2 
and thereby partially inhibit VACV-induced NF-κB activity. Proteins K7 and K1 inhibit TLR-
induced signalling (K7) and prevent IκBα degradation (K1), respectively. Finally, protein E3 
inhibits NF-κB activity in both dsRNA-dependent protein kinase PKR-dependent and -
independent manners (Myskiw et al., 2009 ), and also by antagonizing the RNA polymerase 
III–dsDNA-sensing pathway . 
1.7 A pro-viral factors 
 
Small interfering RNA (siRNA) screens are a good way to identify host proteins involved in 
virus interactions. A range of pro and anti-viral host factors (HF) were identified through an 
siRNA screen carried out in Dr Beard’s laboratory, which found 300 cellular proteins which 
significantly influenced the replication and spread of VACV(Beard, Griffiths et al. 2014). 
Many of the pro-viral HFs were involved in translation of mRNA, while a number of anti-
viral proteins played roles in cellular transcriptional processes and DNA repair pathways. A 
number of the cellular proteins detected had never before been linked with poxviral 
replication including MAST3 and nucleoporins (NUPs).  
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The MAST or microtubule-associated serine/threonine kinase family contains four members 
(MAST1-4). MAST1 is most expressed in the brain. At neuromuscular synapses, MAST1 
binds to TRAF6 and inhibits the ubiquitination and therefore activation of NF-κB, playing an 
important role in regulating inflammatory responses (Xiong, Li et al. 2004). The MAST2 
protein has been found playing a role in the NF-kB pathway via the binding and stabilization 
of TRAF6 (Zhou, Xiong et al. 2004). MAST3 is predicted to contain a serine/threonine 
protein kinase domain near the N terminus which accounts for phosphorylation of the OH 
group of serine or threonine residues in substrate proteins. A PDZ protein binding domain 
located at the C terminus of the 143kDa peptide. Previous studies suggested MAST3 is a 
modulator of the inflammatory response by maintaining the activity of the TLR4-mediated 
nuclear factor kappa B (NF-kB) pathway (Labbe, Goyette et al. 2008). A later study identified 
a group of genes that are modulated by MAST3. These included a number of pro-
inflammatory genes including pro-inflammatory cytokines, regulators of NF-kB, interferon 
inducing that defense against pathogen invasion and genes involved in cell adhesion and/ or 
migration (Labbe, Boucher et al. 2012). 
1.9 Nuclear pore complex (NPC) and nucleoporins (NUPs)  
 
Two VACV siRNA screens (Sivan and Beard) found nucleoporins (NUPs) as pro-viral host 
factors of VACV replication. This is interesting since VACV independent of the cell nucleus 
until late in the replication cycle when virions are undergoing the final stages of assembly 
(Pennington and Follett 1974, Hruby, Guarino et al. 1979). It is unclear which maturation 
process is facilitated by the nucleus or how this facilitation is achieved.  
The nuclear pore complex (NPC) is the gateway between the nucleus and cytoplasm in 
eukaryotic cells. It is comprised of about 30 distinct proteins, termed nucleoporins (NUPs) 
(Rout, Aitchison et al. 2000, Cronshaw, Krutchinsky et al. 2002, Kau, Way et al. 2004). It acts 
as a transport channel, and has an eightfold symmetrical framework spanning the inner and 
outer membranes of the nuclear envelope. In this transport channel, unfolded domains 
containing FG repeats that found on NUPs are docking sites for transport receptors (Kau, Way 
et al. 2004). Ions and small molecules are allowed free passage through NPCs, but larger 
molecules over approximately 20-40kDa are actively transported through NPC by signal 
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identification (Rout, Aitchison et al. 2003, Suntharalingam and Wente 2003, Weis 2003, Kau, 
Way et al. 2004).   
Most proteins that are actively transported into or out of the nucleus through the NPC require 
an interaction between a short amino acid motif and soluble transport receptors. The short 
amino acid motif on the target protein transporting in or out is termed a nuclear localization 
signal (NLS) or nuclear export signal (NES), respectively (Wente and Rout 2010). Importins 
and exportins are soluble transport receptors (generally named karyopherins) that bind to 
cargo through their cargo binding domain. Karyopherins also contain a NPC-binding 
domain(s) and an N-terminal-binding domain for the small GTPase Ran. Ran alternates 
between GDP- and GTP- bound states to regulate the association and dissociation of the 
transport receptor-cargo complex (Lee, Cansizoglu et al. 2006, Wente and Rout 2010). 




1.10 Nuclear export 
 
There are two major nuclear export pathways. One depends on CRM1 (chromosome region 
maintenance 1, also known as exportin 1) and the other on NXF1 (also known as TIP 
associated protein TAP). Gene expression requires nuclear export pathways since mRNA 
must be exported from the nucleus. The NXF1 pathway is the main mRNA export receptor in 
humans (Fornerod, Ohno et al. 1997, Stade, Ford et al. 1997, Gruter, Tabernero et al. 1998). It 
binds with the target mRNA and recruits export receptors to form the transcription-export 
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(TREX) complex. This complex also consists of multisubunit THO complex, UAP56-ATP 
(also known as HEL) export factors and REF (also known as ALY). UAP56, an ATP-
dependent RNA helicase, plays a role in mRNA splicing and TREX complex assembly. 
UAP56 binds REF once attained ATP and facilitates the interaction of REF and mRNA 
(Melchior 2001). 
1. 11 Nuclear import 
 
The import of proteins into the nucleus involves the importin-β receptor. Importin-β interacts 
with the amino acid sequence of NLS (nuclear localization signal) indirectly and requires the 
participation of other proteins which are members of importin-α family. Importin-α directly 
recognize NLS by NLS-binding domain that contain 10 arginine-rich motif repetitions. 
Although importin-α directly interact with NLS, the formation of importin-α and importin-β 
complex facilitates the recognition of NLS containing protein. Importin-α interacts with 
importin-β through the importin beta binding (IBB) domain localized in the N-terminal region 
of importin-α. Interaction between importin-β and the FG domains of nucleoporins on NPC 
initiates the translocation of import complexes. Once in the nucleus, the presence of RanGTP 
dissociates the import complexes, which releases the cargo. The RanGTP- importin complex 
exports back to the cytoplasm where importin is released by RanGAP mediated GTP 
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Figure 3.  The RanGTPase cycle in nuclear protein import and export 
(Melchior 2001). Ran is important in translocation of protein, including RanGAP1 
(GTPase-activating protein1)-mediated GTP hydrolysis in the cytoplasm and 
RCC1 (Regulator of chromosome condensation 1) mediated conversion of 
RanGDP to RanGTP in nucleus. Importin β carries the NLS-containing protein 
into the nucleus by binding NLS motifs. The cargo is released as RanGTP binds 
to importin β in the nucleus. A RanGTP-importin β complex is formed. This 
complex then translocate into cytoplasm and release importin β by RanGAP1-
mediated GTP hydrolysis, which provides free importin β for cargo in another 
cycle. Finally, Ran-GDP re-enters the nucleus where it is converted back to 
RanGTP by RCC1. Notably, exportin CAS, an importins export receptor, is 
essential in export of the RanGTP-importin β complex. In the cycle of nuclear 
export, RanGTP in the nucleus binds with the nuclear export receptor exportin. 
Noticeably, exportin has two binding sites therefore it can bind both cargo and 
RanGTP. This complex translocates onto the cytosolic side of the NPC where 
RanGAP stimulates the hydrolysis of GTP to produce RanGDP. Cargo and 
RanGDP then release from exportin. After that, exportin returns the nucleus for 
another cycle.  
1.12 Viral subversion of nuclear transport 
 
During infection, viruses can disrupt nuclear transport pathways to manipulate cellular 
processes and suppress the host’s antiviral mechanisms, thereby facilitating viral replication. 
Human rhinovirus (HRV) and polivovirus (PV) are cytoplasmic replicated positive strand 
RNA viruses. In order to inhibit host antiviral defense pathways PV and HRV can express a 
viral 2A protease (2Apro) to disrupt the translocation of important cellular proteins involved 
in immunity. 2A protease (2Apro) expressed during infection leads to the proteolytic 
degradation of several nucleoporins, including NUP62, NUP98 and NUP153 and possibly 
other factors (Gustin and Sarnow 2001, Gustin and Sarnow 2002, Park, Katikaneni et al. 
2008, Castello, Izquierdo et al. 2009, Park, Skern et al. 2010, Watters and Palmenberg 2011). 
Mislocalization of cellular protein is also observed during PV and HRV infection of the 
mammal cell, which required the Kapα/Kapβ1 import pathway (Gustin and Sarnow 2001, 
Gustin and Sarnow 2002). 
Encephalomyocarditis virus (EMCV) is another positive stranded RNA virus that interferes 
nucleocytoplasmic transport. By hyperphosphorylating the NUPs, EMCV leader (L) protein 
can alter NUP62, NUP 153 and NUP214 in an L protein-dependent manner, modifying the 
integrity of receptor-cargo complex (Porter and Palmenberg 2009). EMCV leader protein also 
suppresses the activity of RanGTPase, which strikingly inhibits the dissociation of cargos and 
transport factors (Porter and Palmenberg 2009). 
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Host invasion by pathogens elicits nucleus import of signal transducer and activator of 
transcription 1 (STAT1) to bind to interferon stimulated response elements (ISRE) expressed 
by interferon (IFN)-inducible genes (Shuai and Liu 2003). The viral open reading frame 6 
(ORF6) protein is expressed by the severe acute respiratory syndrome coronavirus 
(SARSCoV), a positive-strand RNA virus. SARS-CoV inhibits STAT1 nuclear translocation 
via ORF6 protein without affecting its phosphorylation. During infection, the nuclear import 
factors Kapα2 and Kapβ1 are binded to the ER/Golgi membrane by which SARS-CoV ORF6 
C-terminus effectively blocks STAT1 nuclear transport (Kopecky-Bromberg, Martinez-
Sobrido et al. 2007, Hussain, Perlman et al. 2008).  
Herpes simplex virus is a DNA virus that interferes with protein nuclear import via the 
Kapα/β1 and Kapβ2 nuclear import pathways. These transportins are associated to the NPC 
through direct interactions with NUP62 (Malik, Tabarraei et al. 2012). Although HSV-1 
drastically affects host nucleocytoplasmic trafficking via viral protein ICP27, viral mRNAs 
can still be exported via mRNA export NXF1/TAP pathway by directly interacting with the 
nuclear export factor Aly/Ref (Chen, Sciabica et al. 2002).   
Many DNA viruses selectively inhibit host mRNA export from the nucleus, while still retain 
the activity of efficient viral mRNAs export. Adenoviruses (AdVs) are double-stranded DNA 
animal viruses. E1B-55K and Ad E4 open reading frame 6 (E4orf6) are two adenoviral 
protein products that account for inhibition of host mRNA nucleus export and promotion of 
late viral mRNA nucleus export (Woo and Berk 2007, Blanchette, Kindsmuller et al. 2008). 
This occurs after E1B-55K and E4orf6 interacting with host proteins which forms a complex 
with E3 ubiquitin ligase activity. One study suggested this complex promotes the degradation 
of an unidentified cellular protein involved in host mRNA export via ubiquitin ligase activity 
(Woo and Berk 2007). Different opinion proposed that interaction of E1B-55K and E1B-AP5 
prevents RNP E1B-AP5 interacting with NXF1, resulting in disruption of NXF1-mediated 
host mRNA export (Bachi, Braun et al. 2000). Evidences above showed different role of viral 
protein within the facilitation of viral replication and inhibition of host antiviral immune 
responses through mediating nucleocytoplasmic trafficking.   
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DNA viruses usually must enter the host nucleus to replicate. However a select groups of 
DNA viruses including poxviruses, asfarviruses and mimiviruses are the exception to this rule 
and replicate entirely or almost entirely in the cytoplasm. The role of the cell nucleus in 
poxvirus replication is unclear. Poxviruses are often described as being able to replicate 
“independent of the nucleus”. However, careful reading of early papers on the subject show 
this is not true. VACV transcription, translation and DNA replication can all occur in 
enucleated cells, however there is a block late in virion maturation which prevents production 
of infectious progeny from these enucleated cells (Pennington and Follett 1974, Hruby, 
Guarino et al. 1979). The mechanism by which the cell nucleus enables VACV virion 
construction is not known, however a recent siRNA screen in the Beard laboratory found 
NUP98 to be a pro-viral host factor (Figure 1.4) and another VACV siRNA screen (Sivan, 
Martin et al. 2013) identified that the nuclear export protein nucleoporin 62 (NUP62) is also 
required. In this second study, knockdown of NUP62 reduced the production of infectious 
VACV in a one-step growth experiment, without affecting virus entry and only modestly 
restricting on DNA replication and early and late viral gene expression. The application of the 
chemical leptomycin B, an inhibitor of nuclear export, to VACV infected cells was also found 
to prevent virus replication. This evidence suggests nucleocytoplasmic transport, and 
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Figure 1.4 siRNA targeting NUP98 significantly reduces the level of VACV-
A5-EGFP expressed fluorescence. The NUP98 siRNA SMARTpool (SP) was 
separated into the four component siRNAs, each targeting different regions of 
the gene, and tested for their effect on VACV replication. HeLa cells were 
transfected with the siRNA and after 48 h the cells infected with a EGFP-tagged 
VACV strain and the level of fluorescence produced compared to that present in 
cells transfected with non-specific siRNA (-C). The percentage difference in 
fluorescence compared to the non-specific siRNA is shown on the y axis. 
Statistically significant differences are labelled (*). Data is adapted from (Beard, 
Griffiths et al. 2014) 
 
1.14 Aims of this project 
 
This study aims to: 
1. Determine the mechanism of function of MAST3 in VACV replication 
2. Elucidate the role of nuclear export on VACV maturation  
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2. Methods 
2.1 Cell and viruses.  
 
HeLa cells, adenocarcinoma human alveolar basal epithelia cells (A549), Human Embryonic 
Kidney 293 cells (293T), Rabbit Kidney (RK-13), African green monkey kidney epithelia 
cells (Vero), African green monkey kidney cell line (BS-C-1 ) and MDCK cells (a kidney cell 
line derived from adult female cocker spaniel ) were grown in Dulbecco’s modified Eagle’s 
medium (DMEM; Life Technologies) supplemented with 50IU/ml penicillin, 50µg/ml 
streptomycin (Sigma) and 10% fatal calf serum (FBS). Cells were incubated at 37°C in a 5% 
CO2 humidity incubator. Recombinant VACV tagged with enhanced green fluorescent protein 
(EGFP) to the VACV core protein A5 (Carter, Rodger et al. 2003) and Western Reserve (WR) 
strains were kindly provided by Geoffrey L. Smith (University of Cambridge, Cambridge, 
United Kingdom). Influenza virus PR8 were provided by Paul Digard. 
2.2 Growing and purifying viral stocks.  
 
To grow enough amount of virus, 5 T175 flasks of RK-13 were seeded in DMEM containing 
10% FBS and antibiotics to get 90% confluency for each virus strain. WR and VACV-GFP 
viruses stock were diluted in DMEM containing 2.5% FBS and antibiotics, and infected Cells 
separately at 0.1 MOI with and incubated 48 hours before collected into 50ml Eppendorfs. 
Cell collection were centrifuged at 3000g for 10 min. The cell pellets then were re-suspended 
in 50ml PBS and spun down again at 3000g for 10 mins. Cells were re-suspended in 10 mM 
Tris-HCl pH9 and incubated on ice at least 15 min. Cells were homogenized with Dounce 
homogenizer and transferred to a 13.5ml screw capped centrifuge tube and spinned at 2000g 
for 5min. The supernatant was removed into a fresh falcon tube on ice by aspirating and 
trickled down the side of the tube on top of the sucrose (36 % w/v) to form a nice layer. The 
tubes were filled and balanced with 10 mM Tris-HCl and spinned in SW28 rotor 
ultracentrifuge at 13500rpm, 80min. The pellet then re-suspended in 1ml Tris-HCl pH9 and 
split into 1.5 screw capped tube with 350 µl for each.  
2.3 SiRNA transfection. 
 
All siRNAs were stored in 1 x siRNA buffer (Dharmacon/Thermo) at -80C at a 
concentration of 20μM, and diluted to 250nM to make a working stock. In order to transfect 
the siRNA into cells, HeLa, Vero, A549 and 293T were seeded on 96-well plate at 5x104 
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cells/ml, 5x104 cells/ml, 1x105 cells/ml and 5x104 cells/ml respectively, and incubated 
overnight in DMEM containing 10% FBS to produce a 70%-80% confluent monolayer. 
Media was then removed and 80µl DMEM containing 5% FBS without antibiotics added to 
each well. The sequences of the DC siRNAs were as follows:  









10 µl Dharmafect 1 transfection reagent (Dharmacon/Thermo Scientific) was diluted in 650 µl 
DMEM without serum and antibiotics to make a final concentration of 1.5% and incubated for 
5 minutes. For each well, 10µl of the diluted Dharmafect 1 transfection reagent was added to 
equal amount of siRNA and incubated for 20 min. Finally 20 µl of the siRNA / Dharmafect 1 
mixture was added to the cells, making a final concentration of siRNA of 25nM, and 
incubated for 48 h at 37°C.  
Transfection also conducted on 6-well plates. 1 x105 cells in 2ml HeLa cells were seeded per 
well and incubated for 24 h at 37°C. Before transfection, media was removed and replaced 
with 1600 µl per well DMEM containing 5% FBS without antibiotics. 10 µl diluted (5 µM 
solution of) MAST3 and DUSP3 small interfering RNA (siRNA) SMARTpool and four 
deconvoluted (DC) MAST3 siRNAs (Sigma-Aldrich) were diluted in 190 µl of 1x siRNA 
buffer (Dharmacon/Thermo) separately. 2µl Dharmafect transfection reagent 
(Dharmacon/Thermo Scientific) was diluted in 198µl DMEM without serum and antibiotics to 
make a final concentration of 1%. For each well, 200µl of diluted Dharmafect transfection 
reagent was added to equal amount of siRNAs dilution and incubated for 20 min. 400 µl of 
this mixture was added to the cells to make a final concentration of 25µM siRNA, incubating 
for 48 h at 37°C.  
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In order to infect cells the overlying media was removed and replaced with virus diluted in 
DMEM containing 2.5% FBS (2.5% DMEM) and antibiotics at the indicated MOI. The virus 
was left on the cells for 1 h at 37°C before being replaced with fresh DMEM containing 2.5% 
FBS (2.5% DMEM). 
2.5 Growth curves 
 
2.5.1 Fluorescent readings 
The level of fluorescence produced by the VACV-A5L-GFP virus strain was used as a 
measurement of virus replication. Fluorescence were measured with Synergy HT MultiMode 
microplate reader (BioTek).  
2.5.2 plaque assay 
6 well plates of confluent BS-C-1 cells were prepared. Samples to be titrated were frozen and 
thawed three time to release the virus from cells then a 10 fold dilution series of each sample 
prepared in DMEM supplemented with 2.5% FBS. BS-C-1 were then infected with the 
dilutions for 1 h before the inoculum was replaced with DMEM containing 2.5% FBS, 
antibiotics and 2% carboxymethyl cellulose (CMC) (Sigma-Aldrich) and incubated for 48 
hours at 37°C. After this time the CMC-DMEM was replaced with crystal violet solution 
(15% methanol, 5% crystal violet (Sigma-Aldrich) in water) for an hour in room temperature. 
The plates were then washed with tap water and the number of plaques present counted. 
Plaque assay for influenza virus, seed MDCK cells in 6-well plate at 0.5x106 cells per well 
(2ml per well). MDCK were infected with sample supernatant at gradient dilution and 
incubated at 37°C for 1 hour. The virus was removed and overlay with 2ml/well Avicell 
(FMC) for 48 hours at 37°C. After that, Avicell was removed and 2ml/well of 10% neutral 
buffered formalin (NBF) (Leica) was added in each well. After 20 mins, NBF was replaced 
with 0.1% toluidine blue /PBS for at least 20 min.  
2.6 Protein harvesting and electrophoresis and immunoblotting.  
 
Cells were collected and lysed in ice-cold lysis buffer (137mM NaCl, 1mM EDTA, 
20MmTris-HCl pH7.4, 0.5% Triton X-100) contained protease inhibitors (150 µl/well for 6-
well plate) using a scraper and incubate on ice for 30 min. Lysates were centrifuged at 
12,000g for 5 min at 4°C and transfer the supernatant to a new eppendof. Cell lysates were 
separated by electrophoresis on 10%/8% SDS-polyacrylamide gels before transferred onto 
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nitrocellulose membranes. Immunoreactive bands were visualized using an Odyssey infrared 
system. MAST3 was detected using direct infrared fluorescence (Li-Cor). Samples were 
prepared by adding 5 µl loading buffer (sample buffer adding 10% Mercaptoethanol) in 15µl 
lysate and boiling for 5 min at 98°C. MAST3 protein was resolved on an 8% Tris-glycine 
SDS-PAGE and transferred to a nitrocellulose membrane. Blots were treated with Odyssey 
blocking buffer (Li-Cor) for 1 h before incubation with MAST3 (1:500, St John’s 
Laboratory), DUSP3 (1:5000, ABGENT), β-actin (1:2000, AbCam) antibodies. Goat anti-
mouse IgG (H+L) DyLight 680 conjugate (1 in 5000, Cell Signaling) and Goat anti-rabbit IgG 
(H+L) Dylight 800 conjugate (1 in 5000, Cell Signaling) were used as secondary antibodies 
and incubated the next day. A washing step with 10% tween-PBS was followed once each 
antibody incubation step was finished. Blotting membranes were scanned in an Odyssey 
scanner, and density of bands was quantified using Odyssey scanning software.  
2.7 Compounds 
 
Nucleozin (N270) and Leptomycin B were obtained from Sigma-Aldrich Cooperation. Novel 
compounds 335 was provided by Karyopharm Therapeutics Inc. Carbenoxolone was provided 
by Sigma-Aldrich, and used as a positive control. DMSO, solvent of Nucleozin, was obtained 
from Sigma-Aldrichand 335 and applied as a negative control.   
2.8 Cell toxicity assay 
 
HeLa and A549 cells were seeded on two parallel 96-well plate at 5x105 cells/ml, and 
incubated overnight at 37°C. Beside infection, cells were pre-treated with compounds for 1 
hour in working dilution. One of the plates infected with specific MOI of virus for 1 hour and 
replaced with new compounds. After 48 hours, added 100µl CellTiter-Blue (Promega) for 
each well of 96-well plate and incubate for 1 hour. Fluorescence was read at 560Ex/590Em 
with Synergy HT MultiMode microplate reader (BioTek). Cell death were represented by the 
percentage of average of living cells in treated groups compared to the average of living cells 
in DMSO control. 
2.9 Statistics 
 
Student’s t-Test (two tail distribution with two-sample equal variance) was used to compare 
data using the Excel statistical package.  
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3. Cellular protein MAST3 facilitates VACV replication 
3.1 MAST3 siRNA causes a reduction in VACV replication in both a 
multi-step and single-step growth curve.  
MAST3 was identified as a pro-viral protein for VACV in a siRNA screen (Beard, Griffiths et 
al. 2014). The aim of this chapter is to investigate in more detail the role of MAST3 in VACV 
replication. In initial experiments the impact of MAST3 on VACV replication was assessed 
using a VACV strain which expresses enhanced green fluorescent protein (EGFP) tagged to 
the A5 viral capsid protein (VACV-A5-EGFP). The levels of the MAST3 protein in HeLa 
cells were knocked down using a SMARTpool of 4 siRNAs designed to target the MAST3 
mRNA transcript. After 48h the cells were infected with VACV-A5-EGFP at a low 
multiplicity of infection (MOI=0.1) and the levels of fluorescence was measured over the 
following 48h as a marker of virus replication. Two negative controls were included in the 
experiment: mock-transfected cells and cells transfected with siRNA targeting VP16, VP16 is 
a protein from encoded by herpes simplex virus type 1 and thus acts as a negative control 
siRNA. A positive-control siRNA targeting PRK-AB1 which is known to inhibit VACV 
replication (Moser, Jones et al. 2010) was also included. Cells were examined microscopically 
for evidence of toxic effects of the siRNA and no difference was detected between treatment 
groups and controls. As shown in Figure 3.1, knockdown of MAST3 using a SMARTpool of 
four siRNAs significantly reduced the levels of fluorescence by 23% when compared to mock 
transfected cells. In comparison the non-targeting control VP16 produced no significant effect 
on fluorescence levels, while the PRK-AB1 control significantly reduced fluorescence levels, 
as expected. To determine whether the reduction in fluorescence caused by the MAST3 
SMARTpool was due to off-target effects, in the same experiment the SMARTpool was 
deconvoluted into the four constituent components. Figure 3.1 shows a significant reduction 
in fluorescence in response to all four individual siRNAs. This result suggests that knockdown 
of MAST3 causes a reduction in VACV replication. 
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Figure 3.1. MAST3 is a pro-viral cellular protein for VACV replication in a 
multistep in HeLa cells. 
HeLa cells were transfected with four siRNAs targeted against MAST3 (MAST3 
(1-4)) and a combined MAST3 SMARTpool (MAST3 SP). In addition four 
controls were included: mock transfected cells, cells transfected with siRNA 
targeting VP16 (non-targeting siRNA), siRNA targeting PRK-AB1 (a known pro-
viral host factor for VACV) and non-transfected non-infected cells. After 48h the 
cells were infected with VACV-A5-EGFP at 0.1 MOI. Fluorescence was 
measured at the indicated times using a Synergy plate reader (Biotek). Average 
fluorescence was calculated from 6 technical replicates and indicated for each 
data point. The data presented are representative of two replicate experiments. 
The error bars indicate standard deviation. The results were analyzed using a 
Student’s t-Test. P values of <0.05 (compared to VP16 siRNA) are noted (*). 
 
In order to determine the stage of the VACV life cycle that is influenced by MAST3 a single 
step growth curve was carried out. The experimental design was similar to that described 
above in the multistep growth curve, however the MOI was 5, ensuring that all cells were 
infected at t=0. Figure 3.2 shows that the SMARTpool siRNA and all four deconvoluted 
siRNAs targeting MAST3 caused a significant reduction in fluorescence. This result suggests 
that MAST3 is required for an early stage in VACV replication such as virus entry, 
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Figure 3.2 MAST3 is a pro-viral cellular protein for VACV replication in a 
single-step in HeLa cells. The same experimental protocol as described for 
Figure 3.1 was used, however the transfected cells were infected with VACV-A5-
EGFP at a higher MOI (5). The data are representative of two biological 
replicates. P values of <0.05 (compared to VP16 siRNA) are noted (*). 
3.2 MAST3 antibody does not detect MAST3 on western blot  
The results described in section 3.1.1 are consistent with the previous results from the siRNA 
screen, and suggest that MAST3 is a proviral host factor for VACV. However, it was essential 
to validate the efficacy of the MAST3 siRNA used in these experiments. This was 
investigated by immunoblotting for the MAST3 protein in HeLa cells transfected with the 
MAST3 siRNA SMARTpool. Briefly, cells were transfected for 48h before being collected 
into protein lysate buffer containing protease inhibitors, separated on a polyacrylamide gel 
and transferred to nitrocellulose membrane and blotted using antibody directed against 
MAST3. Antibody directed against actin was included as a loading control. The MAST3 gene 
encodes a protein of predicted size 143kDa. In Figure 3.3 actin band is visible at 42kDa and 
of consistent intensity showing equal loading of samples. The band was also of consistent 
intensity across the treatment groups with no evidence of knockdown of the protein in the 
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Figure 3.3. MAST3 knockdown of MAST3 protein by siRNA could not be 
detected by western blot. 
HeLa cells were transfected with siRNAs targeted against MAST3 (MAST3 (SP)). 
In addition three controls were included: mock transfected cells, cells transfected 
with siRNA targeting VP16 (non-targeting siRNA) and cells of non-transfected. 
After 48h transfection, cells were collected and the level of MAST3 protein in the 
cell lysates was probed using western blotting with anti-MAST3 antibody and 
anti-actin antibody. 
 
To determine if the 70kDa band detected by the anti-MAST3 antibody was the product of 
degradation the experiment was repeated using fresh protease inhibitors in the lysate buffer 
and keeping samples on ice between collection and loading on the gel. In addition, in order to 
separate the higher molecular weight protein bands more clearly the percentage of acrylamide 
was lowered 10% to 8% and the gel run for longer. No protein of 143 kDa was detected by the 
anti-MAST3 antibody however a band of 70kDa was again present, with the intensity of the 
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Figure 3.4. A band representing MAST3 protein of right size in HeLa cells 
could not be detected by western blot. HeLa cells were transfected with 
siRNAs targeted against MAST3 (MAST3 smartpool (SP)). In addition controls 
were included: mock transfected cells, cells transfected with siRNA targeting 
VP16 (non-targeting siRNA). After 48h transfection, the cells were collected and 
level of MAST3 protein in the cell lysates was detected using western blotting 
with MAST3 antibody and actin antibody.  
 
A possible explanation for the lack of a MAST3 band at 143kDa is a mutation in the MAST3 
open reading frame in HeLa cells. HeLa cells are known to be widely mutated (Landry, Pyl et 
al. 2013). In order to investigate this possibility the presence of MAST3 in other cell lines was 
investigated. Lysates of A549, Vero, 293T and HeLa cells from one well of a confluent 6-well 
plate were analyzed using the same antibody directed against MAST3 (Figure 3.5). Each cell 
line displayed same pattern of protein analysis as HeLa cells, with a strong band at 70kDa and 
no band at 143kDa. A large protein (approximately 250kDa) was detected in only 293T cells. 
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Figure 3.5. MAST3 protein of right size could not be detected, in A549, 
293T, Vero or HeLa cells. 
The protein lysates were collected from untransfected Hela, Vero, 293T and 
A549 cells. Level of MAST3 protein in the cell lysates was compared using 
western blotting (with MAST3 antibody; and actin antibody).  
 
Another possible explanation for the 70kDa band detected by the MAST3 antibody is the 
presence of an alternative start site within the MAST3 ORF which produces a smaller size 
protein. The MAST3 transcripts were investigated using Ensembl (www.ensembl.org) which 
indicates that the full length mRNA transcript is the only protein encoding transcript produced 































































































































These results suggest the 70kDa band detected by the anti-MAST3 antibody is a non-specific 
cross-reacting background protein. The failure of the antisera to detect a 143kDa protein on 
Western blot could be due to poor quality antibody. We therefore changed to an alternative 
method of measuring MAST3 mRNA levels is using quantitative reverse transcription PCR. 
In order to generate sufficient mRNA for these experiments the siRNA transfection protocol 
was scaled up from a 96 well plate to a 6 well plate format.  
3.3 Effect of MAST3 siRNA on HeLa cells in a 6 well plate 
Initially the effect of MAST3 siRNA on VACV replication in a 6 well plate was examined. 
Briefly, HeLa cells were plated in a 6 well plate at a confluency of 70% and transfected with 
siRNA targeting MAST3 (SMARTpool and deconvoluted), PRK-AB1, VP16 (at a final 
concentration of 25nM) or mock transfected. After 48 h the cells were either infected with 
VACV-A5-EGFP at an MOI of 5 or collected and stored at -70C. The fluorescence levels in 
the virally-infected wells were measured over the following 48 h. This experiment was 
repeated 6 times and produced inconsistent results (data not shown), indicating that procedure 
required optimisation before this technique could be used to examine the impact of MAST3 
on VACV replication. Previous work has suggested that siRNA transfection efficiency of 
HeLa cells drops after approximately 15 passages (Scientific 2015), therefore a new vial of 
low passage HeLa cells were grown up and used however the results were still inconsistent 
(data not shown). Repeated freeze/thaw cycles can cause degradation of siRNA therefore a 
new aliquot of MAST3 siRNA was used but also continued to produce inconsistent results 
(data not shown).  
The next optimisation step was to examine the effect of increasing MAST3 siRNA 
concentrations. HeLa cells in a 6 well plate were transfected with a gradient of siRNA 
concentration from 25nM, 50nM to 100nM before infection with VACV-A5-EGFP and 
fluorescence measurement (Figure 3.7).    
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  Figure 3.7. siRNA transfections in a 6 well plate format produce abnormal 
results. 
HeLa cells were transfected with varying concentrations of siRNA targeted 
against MAST3 (siRNA SP). In addition, four controls were included, i.e. mock 
transfected cells, cells transfected with siRNA targeting VP16 (non-targeting 
siRNA), siRNA targeting PRK-AB1 (a known pro-viral host factor for VACV) and 
non-transfected& uninfected. 
 
Increasing concentrations of MAST3 siRNA caused incremental reductions in viral 
fluoresence, as expected, however the fluorescence in wells transfected with PRK-AB1 
siRNA (positive control) was higher than VP16 (negative control). In addition fluorescence in 
wells transfected with MAST3 (25nM) siRNA was higher than mock transfected cells 
(negative control). In the absence of the expected outcomes of the control treatments the 
results from this experiment could not be interpreted. 
3.4 Knockdown of DUSP3 using siRNA in a 6 well plate produces 
variable results. 
In order to optimise siRNA transfection in a 6 well plate more easily siRNA targeting the 
DUSP3 protein was used. DUSP3 is dual specificity protein phosphatase 3 which has 
previously been shown in the Beard laboratory to act as a pro-viral protein (unpublished data). 
In contrast to MAST3, there is a clean and strong anti-DUSP3 antibody available which 
allowed western blotting to be used to quantify the efficacy of siRNA knockdown. As a 
further trouble-shooting step a new vial of transfection reagent (Dharmafect 1) was bought 
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and its performance compared to the old vial. HeLa cells were transfected with siRNAs 
targeted against DUSP3 using new purchased Dharmafact and old Dharmafact. In addition 
three controls were included: mock transfected cells, cells transfected with siRNA targeting 
VP16 (non-targeting siRNA) and non-transfected cells. After 48h transfection, cells were 







Figure 3.8. Knockdown of DUSP3 protein by siRNA in HeLa in a 6 well plate 
format was successfully as detected by western blot. 
HeLa cells were transfected with siRNAs targeted against DUSP3 using new 
purchased Dharmafact and old Dharmafact. In addition three controls were 
included: mock transfected cells, cells transfected with siRNA targeting VP16 
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were lysed for western blot and probed with antibody against DUSP3 and actin 
(A). Intensity of the bands was determined using Odyssey (Licor) software (B).  
 
The western blot (Figure 3.8A) revealed an actin band at 49kDa in all lanes, but with some 
variation in intensity between samples. Licor quantification was therefore used to correct for 
this. Figure 3.8B shows the levels of DUSP3 were similar in the cells transfected with VP16 
or mock transfected. In contrast, in HeLa cells transfected with siRNA targeting DUSP3 the 
levels of DUSP3 (compared to VP16 siRNA transfected cells) were 34.37% (new 
Dharmafact) and 28.94% (old Dharmafact), indicating the siRNA successfully knocked down 
the levels of DUSP3 and the siRNA protocol had worked. 
The experiment was then repeated using identical conditions and reagents to assess the 
reproducibility of siRNA transfection in a 6-well plate format. Two additional siRNAs were 
included in the repeat, targeting MAST3 (SMARTpool) and PRK-AB1, in addition to a non-
transfected control (Figure 3.9). In addition, there was little difference between the old and 




Figure 3.9. DUSP3 siRNA failed to consistently knock down DUSP3 protein 
levels. HeLa cells were transfected with siRNAs targeted against MAST3 and 
DUSP3. In addition four controls were included: mock transfected cells, non-
transfected cells, cells transfected with siRNA targeting VP16 (non-targeting 
siRNA) and siRNA targeting PRK-AB1 (a known pro-viral host factor for VACV). 
After 48h transfection, cells were lysed for western blot with antibodies targeting 
DUSP3 (green) and actin (red).  
 
In order to investigate the reproducibility of the 6 well plate siRNA transfection in more 
detail, two experiments were carried out at the same time in parallel by two scientists. All 
 
36 
Master of Science by Research  University of Edinburgh  2016 
 
experimental parameters and reagents were identical except the operator. As described 
previously, HeLa cells were seeded in 6 well plates, transfected with siRNA targeting VP16 
(non-targeting protein), PRK-AB1 (a known pro-viral host factor for VACV), MAST3 
SMARTpool, or mock transfected. After 48 h the cells were infected with VACV-A5-EGFP 
at an MOI of 0.1 and fluorescence measured over the following 48 h. As shown in Figure 15 
the results obtained by scientist 1 (Figure 15A) were not the same as scientist 2 (Figure 15B). 
This confirms the inconstant nature of the siRNA transfection in a 6 well plate format.  
 
 
Figure 3.10 Transfection of siRNA into HeLa cells in a 6 well plate was 
susceptible to operator effect. Two operators (A) scientist 1 and (B) scientist 2 
conducted an identical transfection & infection experiment on 6 well plate HeLa 
cells. Four controls were included: cells were mock transfected, transfected with 
siRNA of VP16 (non-targeting protein), PRK-AB1 (a known pro-viral host factor 
for VACV) and cells of Non-transfected & non-infected. MAST3 SP was applied 
here for MAST3 protein knockdown. After 48h transfection, cells were infected 
with VACV-A5-EGFP at 0.1 MOI. Fluorescence was measured at the indicated 
time points.  
 
The ability to knock down protein levels using siRNA in a 6 well plate was crucial to the 
success of this project. Extensive troubleshooting and optimisation work had consistently 
produced erratic results. As a result this project was halted and research into a different topic, 
the influence of nuclear export on VACV replication, begun.  
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Many DNA viruses replicate their viral genome within the nucleus, relying on nuclear 
proteins of the host cells for critical functions. VACV is an unusual DNA virus since it 
encodes a complete DNA replication, transcription and translation machinery which enables it 
to carry out these functions in the cytoplasm and in the absence of a nucleus (Pennington, 
1974 #362, Tolonen, 2001 #364). However, the nucleus is required for assembly of the mature 
VACV virion. How the nucleus contributes to VACV assembly is unknown, although recent 
work has identified nuclear transport, in particular nuclear export, as being crucial (Sivan, 
Martin et al. 2013). In this chapter the impact of nuclear export on VACV replication was 
investigated using chemical inhibition. Four chemicals were used in the study:  
 Leptomycin B is an inhibitor of CRM1, also known as exportin 1, the major nuclear 
export receptor.  It has been shown to have significant anti-viral effect, for example 
against influenza virus and human immunodeficiency virus type 1 (HIV-1). LMB has 
shown significant toxic effects in vivo, which makes it unsuitable for therapeutic use. 
 335 is a novel compound produced by the company Karyopharm as a less toxic 
alternative to LMB. It has a similar mechanism of function, inhibiting CRM1-
dependent nuclear export.  
 Nucleozin inhibits IAV replication by two different ways. At early stages, nucleozin 
inhibits the synthesis of viral proteins and all classes of RNA. At later stages, once the 
viral ribonucleoproteins (RNPs) have formed and exited from the nucleus, nucleozin 
blocks the cytoplasmic trafficking of the RNPs, promoting the formation of large 
perinuclear aggregates of RNPs along with cellular Rab11 (Amorim, Kao et al. 2013). 
Nucleozin does not inhibit nuclear transport and is used as a positive control in this 
work for inhibition of IAV replication. 
 Carbenoxolone inhibits VACV replication and was used as a positive control in this 
work. It has no known function on nuclear transport.  
In addition the chemical DMSO, the solvent of nucleozin and 335, was used as negative 
“carrier” control. 
The impact of the compounds in two cell lines – HeLa and A549 – was tested to ensure the 
changes identified were not cell-specific. 
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To investigate the impact of the chemicals used in this study on cell viability, HeLa and A549 
cells were treated with the panel of compounds and the level of cell viability measured. The 
concentrations used in the dilution series are listed in Table 4.1 and based on concentrations 
used in previous similar studies.  
Briefly, HeLa cells and A549 cells were plated at 100% confluency and treated with varying 
concentrations of compounds (nucleozin, leptomycin B, 335, carbenoxolone) for 48 h. DMSO 
was diluted in media from 1 in 100 to 1 in 72900 in a 3-fold dilution (the same dilution 
protocol as nucleozin) as a carrier control. The cell viability was then determined using 
CellTiter-Blue (Promega) which measures the conversion of a redox dye (resazurin) into a 
fluorescent end product (resorufin). Nonviable cells rapidly lose metabolic capacity, are 










0  0  0  0  0 
0.1  1  0.1  1/72900  10 
0.3  3  0.3  1/24300  30 
1  10  1  1/8100  100 
3  30  3  1/2700  300 





Table 4.1. The concentration ranges used in these studies for each of the 
four drugs, and the dilutions of DMSO. Nucleozin and 335 were diluted 3-fold 
in DMSO. Leptomycin B and carbenoxolone were diluted 3-fold in DMEM media.  
 
Figure 4.1 shows the percentage of viable cells in compound treated cells compared to 
untreated cells. In general HeLa cells were slightly more sensitive than A549 cells to the toxic 
effects of the compounds. In both cell lines the cell viability dropped in response to increased 
drug concentration, however this reached 50% cell death in only the leptomycin B treated 
HeLa cells at the highest concentration (100nM). For other compounds, they need higher 
concentration than I test to reach CC50. From these results, a suitable concentration for each 
compound was decided, i.e. 10	μM nucleozin, 30nM 335, 30nM leptomycin B and 150 μM 
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Figure 4.1 Cell viability of HeLa cell and A549 decreasing with increasing 
concentration of Nucleozin, Leptomycin B and 335. HeLa cells and A549 
cells were treated with serial dilution of compounds (nucleozin, leptomycin B, 
335, carbenoxolone) or DMSO as a negative control and incubated at 37C for 
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48 hours. CellTiter-Blue was then used to estimate the number of viable cells 
present in multiwell plates via a fluorometric method. CC50 is indicated on the 
figure as a dotted line. Data shown are an average ± standard deviation of three 
technical replicates and representative of two biological replicates.  
 
4.2 Nucleozin, carbenoxolone, leptomycin B and novel compound 335 
inhibit IAV replication 
 
Nucleozin, leptomycin B, 335, and carbenoxolone are all known to inhibit the replication of 
influenza virus A (IAV) (Watanabe, Takizawa et al. 2001, Amorim, Kao et al. 2013). To 
confirm that the compounds used in this study were active, their impact on IAV replication 
was investigated. A549 and MDCK cells were used in this experiment since IAV replicates 
poorly in HeLa cells. A549 and MDCK cells were pre-treated with each compound (30nM 
leptomycin B, 30nM 335, 10 μM nucleozin and 150 μM carbenoxolone or DMSO as a 
negative control) for 1 h, then infected with IAV strain PR8 at an MOI of 0.01 for 1 h (drugs 
were present during this time). The inoculum was then replaced with fresh media plus drug 
and the cells incubated for 48 h. Supernatant was then collected at 0, 24 and 48 h post 
infection and the amount of IAV present titred on MDCK cells. As shown in Figure 4.2 the 
virus grew to high titres (over 107 pfu/ml) in untreated cells, as expected. The viral titre in the 
supernatant of cells treated with DMSO were very similar to the untreated cells, indicating 
that 1/100 (v/v) DMSO has no detectable impact on the replication of IAV. In contrast 
nucleozin treatment resulted in a clear reduction in IAV replication with a greater than 4 log10 
reduction in virion production detected in A549 cells and greater than 3 log10 reduction in 
MDCK cells. Leptomycin B and 335 also markedly inhibited IAV replication by at least 2 
log10 in both cell lines. Carbenoxolone also inhibited IAV replication in both A549 and 
MDCK cells by at least one log10. These results are consistent with previous studies that 
revealed Nucleozin, 335 and Leptomycin B all inhibited IAV replication (Watanabe, Takizawa 
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Figure 4.2 Nucleozin, carbenoxolone, leptomycin B and 335 treatment 
reduce influenza virus PR8 growth in A549 and MDCK. IAV multistep growth 
curve in (A) A549 cells and (B) MDCK cells that treated with 10µM nucleozin, 
150µM carbenoxolone, 30nM leptomycin B, 30nM 335 and 1/100 DMSO. A549 
and MDCK cells were pre-treated for 1 hour with compounds followed by 
infection with IAV PR8 (0.01 MOI). Supernatant was collected at the indicated 
times and virus titred on MDCK cells. 
 
 
4.3 Impact of the compounds on VACV replication. 
 
Having shown that the compounds exhibited antiviral activity against IAV, the effect of the 
compounds against VACV was investigated, with particular interest in the impact of the two 
nuclear export inhibitors leptomycin B and 335. Initially the impact of the compounds on the 
replication of the VACV-A5-EGFP virus strain was measured using the levels of EGFP 
fluorescence as a surrogate for virus replication. Briefly, HeLa and A549 cells were pre-
treated with a range of concentrations of each compound (Table 4.1) for 1 h, followed by 
infection with VACV-A5-EGFP for 1 h during which the compounds were present. The virus 
was then removed and fresh media containing compounds added and the cells incubated for 








Figure 4.3 The response of VACV to a range of concentrations of nucleozin, 
leptomycin B, 335 and carbenoxolone in HeLa and A549 cells. HeLa cells 
and A549 cells were pre-treated with compounds and followed infection with 
VACV-A5-EGFP and fluorescence measured.  
Figure 4.3 shows that DMSO had little effect on virus replication compared to untreated cells 
until high concentrations of DMSO were reached. Carbenoxolone, as expected, caused a large 
reduction in fluorescence levels in both cell lines at 30-100nM and nucleozin caused a gradual 
reduction in fluorescence as drug concentration increased. However neither carbenoxolone or 
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nucleozin caused a 50% reduction in fluorescence levels. As previously published, leptomycin 
B caused a reduction in viral fluorescence with IC50 of 14.69nM in HeLa cells and 15.07nM 
in A549 cells. Surprisingly, novel compound 335, which has the same mechanism of action as 
leptomycin B, had very little effect on fluorescence levels, with less than 20% reduction in 
fluorescence even at high concentrations. This suggested the reduction in fluorescence seen in 
leptomycin B treated cells may have been due to an off-target effect. Indeed, when the cells 
were examined under light microscopy, substantial cell death could be seen in the wells 
treated with higher concentrations of leptomycin B. In order to quantify the amount of cell 
death seen in compound-treated and virus-infected cells, CellTiter-Blue was added to the 
wells 48 h post infection and fluorescence read (Figure 4.4). The profile of cell death was 
remarkably similar to the profile of viral fluorescence. This was particularly striking in the 
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Figure 4.4 Leptomycin B causes cell death in VACV-infected cells. HeLa 
cells and A549 cells were pre-treated with compounds for 1 h, followed 0.01 MOI 
infection with VACV-A5-EGFP for 1 h. Cells were further incubated in fresh 
media containing compounds for 48 h. Cell viability was measured with CellTiter-
Blue. The data shown are average of three technical replicates and 
representative of three biological replicates. Error bar are standard error of the 
mean.  
Comparison of the data in Figures 4.3 and 4.4 strongly suggest that cell death caused the 
reduction in virus fluorescence seen in leptomycin B treated cells, rather than inhibition of 
viral replication. To further investigate the accurate level of the virus reduction produced from 








Figure 4.5 Inhibition of CRM1 nuclear export pathway does not inhibit 
VACV replication. Data from Figure 4.3 (viral fluorescence) were corrected 
using data from Figure 4.4 (cell death data) to produce an estimate of the 
“fluorescence per cell present”.  
The virus fluorescence was very similar to DMSO-treated cells for all compounds at all 
concentrations except carbenoxolone, indicating only carbenoxolone has an anti-VACV effect, 
and highlighting the importance of measuring cell death when investigating anti-viral effects. 
Calculating the selective index of the compounds (Table 4.2) is another way of determining 
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Table 4.2. List of established and experimental drugs for testing in 













 - Represents the concentration of a drug that is required for 50% 
inhibition in vitro 
2CC
50
- Represent the concentration of a drug that is required for 50% 
cytotoxicity  




The selective index could only be calculated for leptomycin B on HeLa cells and 
was 3.98. Ideally the selective index should be high, indicating the drug has an 
antiviral effect in the absence of any cell toxicity effects. 3.98 is a small SI and 
indicates leptomycin B causes antiviral and cellular toxicity at similar 
concentrations.   
4.4 Leptomycin B has no significant effect on Vaccinia virus yield.  
 
The previous experiments used EGFP fluorescence measurements to estimate the level of 
VACV replication. While this is a convenient and often-used method of determining viral 
growth it is not a direct measure of infectious virus production. In order to determine if 
leptomycin B, 335, carbenoxolone or nucleozin inhibit the production of infectious VACV 
virions we used viral plaque-forming assays. A549 and HeLa cells were pre-treated with 
compounds (30nM leptomycin B, 30nM 335, 10 μM nucleozin and 150 μM carbenoxolone) 
for 1 h, and infected with VACV-WR (0.01 MOI) for a multistep infection. 1 h post infection 
cells were further incubated in fresh media with compounds for 48 h. Cells and supernatant 
were collected together at 24 h and 48 h post infection and virus titrated using a plaque assay 






HeLa  ‐  93.3  ‐ 
A549  ‐  ‐  ‐ 
Leptomycin B 
HeLa  22.69  90.3  3.98 
A549  22.69  ‐  ‐ 
335 
HeLa  ‐  ‐  ‐ 
A549  ‐  ‐  ‐ 
Carbenoxolone 
HeLa  ‐  ‐  ‐ 
A549  ‐  ‐  ‐ 
DMSO 
HeLa  ‐  ‐  ‐ 
A549  ‐  ‐  ‐ 
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Figure 4.6 Nuclear export inhibitor have no significant effect on the 
production of VACV virions. A549 and HeLa were pre-treated with compounds 
(30nM leptomycin B, 30nM 335, 10 μM nucleozin and 150 μM carbenoxolone, 
respectively) for 1 h, then infected with VACV (0.01 MOI) for a multistep growth 
curve. Cells and supernatant were collected together at 24-h and 48-h time point 
for plaque assay. Data shown were average of two biological replicates. Error bar 
shows the standard error of the mean. 
DMSO and untreated cells yielded high VACV titres of approximately 108 pfu/ml on A549 
cells and over 107 pfu/ml on HeLa cells. VACV was completely inhibited on both A549 and 
HeLa cells treated with 150 μM carbenoxolone with no plaques detected at 48 h. No 
statistically significant difference in titre was detected in nucleozin, leptomycin B or 335 
treated cells compared to DMSO or untreated controls. In particular, leptomycin B inhibited 
VACV replication on A549 and HeLa by 1.6 fold (p-value=0.67) and 3.3 fold (p-value=0.074) 
compared to untreated cells. These results confirm that neither leptomycin B or 335 have a 
significant effect on VACV virion production, consistent with the result from fluorometric 










MAST3 was previously identified as a regulator of NF-κB activity, therefore it was a priority 
hit from the siRNA screen carried out in Dr Beard’s laboratory. The initial hypothesis was that 
VACV uses MAST3 to evade host antiviral defences via inhibition of the NF-κB pathway. 
NF-κB is a major transcription factor which rapidly activates innate and adaptive immune 
responses, and is a key antiviral defence mechanism. VACV is known to evade the NF-κB 
pathway multiple different ways, and modulating MAST3 activity could represent another 
example (Labbe, Goyette et al. 2008, Labbe, Boucher et al. 2012). Initial results revealed a 
reduction in virally-encoded fluorescence in response to MAST3 siRNA whichwas consistent 
with this hypothesis. Unfortunately after these initial promising results there were technical 
difficulties with the project which prevented us from proving or disproving the theory. 
The MAST3 antibody did not detect a protein band of the correct size (143kDa) from a range 
of cell types on a western blot. A lower band of 70kDa that was consistently detected by the 
antibody was most likely a non-specific band. The absence of a 143kDa band suggested the 
MAST3 protein was either expressed at levels too low to detect using this technique, or that 
the antibody was poor quality and unable to detect the protein. One trouble-shooting step 
which could be tried in the future would be to over-express a recombinant MAST3 protein 
from a plasmid and test whether the antibody detects the over-expressed protein. The MAST3 
siRNA could then have been employed in cells over-expressing MAST3 to determine if it 
reduces protein expression. We chose to change to a different method of detection of protein 
expression and use quantitative polymerase chain reaction (qPCR) to calculate the amount of 
MAST3 mRNA present. This required a move to a six well plate format rather than the 96 
well plate format that had been used up till then. Unfortunately the siRNA transfection 
method did not produce consistent results in this different format despite intensive trouble-
shooting and optimisation. This project was therefore shelved due to time constraints 
associated with a one year research project. 
If time had permitted the project to be continued, a new method of modulating MAST3 
protein expression could have been used, for example CRISPR/Cas 9 genetic modification, 
short hairpin RNA (shRNA), or using mouse embryo fibroblasts isolated from MAST3 
knockout mutant mice. Alternatively, overexpression of MAST3 on a plasmid may produce a 
reversed phenotype and could be used to investigate the function of MAST3 protein in VACV 
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replication.  
The second project reported in this Masters thesis was an investigation into the role played by 
the host cell nucleus in poxvirus replication. Again, we used VACV as our prototype poxvirus. 
Poxviruses famously replicate soley in the cytoplasm (Morgan, Ellison et al. 1954), an 
unusual strategy for a DNA virus. Work published over 40 years ago reported that despite the 
cytoplasmic location of VACV replication, the virus still requiresthe cell nucleus for 
successful virion morphogenesis (Pennington and Follett 1974). This finding was 
subsequently supported by other researchers (Hruby, Guarino et al. 1979).  More recently 
two siRNA screen papers (Sivan, Martin et al. 2013, Beard, Griffiths et al. 2014) both 
identified NUPs, which are involved in nucleocytoplasmic transport, to be strong proviral host 
factors. One paper also reported an anti-viral effect exerted by the nuclear export inhibitor 
leptomycin B which specifically inhibits the CRM1 export pathway (Sivan, Martin et al. 
2013). This body of work suggests that VACV requires the host cell nucleus for one of the 
final stages of replication – the maturation of the virion particle. In order to investigate this 
further we used leptomycin B and another CRM1 pathway inhibitor known as 335. Initial 
experiments investigated the toxic potential of the compounds and then confirmed their 
activity by using them to reduce the replication of IAV. The effect of the compounds against 
VACV was then tested using a fluorescently labelled VACV strain. In these experiments the 
level of fluorescence was measured as a proxy of virus replication. A reduction in replication 
was seen in response to the positive control compound carbenoxolone and also leptomycin B, 
however 335 had no effect on fluorescence levels. This conflict in findings between the two 
CRM1 pathway inhibitors was solved when the level of cell death was examined. Leptomycin 
B treatment plus VACV infection caused significant cell death, whereas 335 did not. When the 
fluorescence levels were corrected for cell death it was clear that the original reduction in 
fluorescence in the leptomycin B treated, VACV infected cells was due to cell death and not a 
reduction in virus replication. The conclusion of this work was that the CRM1 pathway is not 
involved in VACV replication. This was strengthened by the final experiment which directly 
measured VACV replication using virus titration. The number of infectious virions from cells 
treated with leptomycin B or 335 and then infected with VACV (wildtype strain) was 
compared to untreated and DMSO treated cells and no significant different was detected.  
In order to put this finding into context with the published literature the previous papers were 
re-examined. Pennington and Follet (Pennington and Follett 1974) carried out their work 
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using a very high MOI (50) which could have led to artifical results. However, Hruby and co-
workers (Hruby, Guarino et al. 1979) used a MOI of 5, and described extensive control 
experiments to prove the enucleated cells were viable for the length of the experiment. They 
clearly showed that VACV can undertake transcription, translation and DNA replication in the 
absence of the host cell nucleus, a remarkable feat of independence. However the host cell 
nucleus is required much later in the VACV life cycle, to allow immature virion particles to 
progress to mature infectious virions. Sivan and co-workers (Sivan, Martin et al. 2013) 
extended this work by describing a pro-viral effect of the NUP62 protein and leptomycin B, 
and suggest VACV requires a functional nuclear-cytoplasmic transport and particularly the 
CRM1 export pathway. However when this paper was examined closely the NUP62 siRNA 
treatment knocked down VACV growth by a small amount, only 1/3rd of a log10. No 
statistical analyses were reported on the significance of this reduction. Equally importantly no 
cell death data was reported, therefore the potentially toxic effect of the NUP62 siRNA may 
not have been taken into account. The effect of leptomycin B treatment on VACV replication 
was reported in the same paper using an unusual method. A fluorescently labelled EGFP-
VACV strain was used, and virus replication in control and leptomycin B treated cells 
compared by counting the number of GFP positive cells. Leptomycin B treatment reduced the 
number of GFP positive cells by 50%, however again no cell death data was reported and no 
statistical analyses included. The effect of leptomycin B on overall levels of fluorescence or 
the production of infectious viral particles (commonly used methods of measuring VACV 
replication) was not reported. In the absence of cell death measurements and statistical 
analyses and the unusual methods used to measure virus replication these findings must be 
viewed with caution.  
While the NUP62 and leptomycin B data (Sivan, Martin et al. 2013) are not entirely 
convincing, data from the earlier enucleation studies are, and are supported by work from the 
Beard laboratory which showed that siRNA targeting the NUP98 protein (which is also 
involved in nucleocytoplasmic transport) significantly reduces VACV replication (Figure 1.4). 
This latter work asessed the levels of cell death caused by the siRNA transfection and 
corrected the fluorescence levels accordingly, and carried out robust statistical analyses on the 
data. Therefore there is undoubtedly evidence that VACV requires a host cell nucleus in order 
to complete its life cycle. The work in this thesis adds to our understanding of this subject by 
showing that the CRM1 export pathway is not required.  
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While the CRM1 transport pathway may not be required, there are alternative 
nucleocytoplasmic transport pathways which may be required by VACV, such as the other 
major nuclear export pathway (NXF1/TAP), or an import pathway. In the future, these could 
be examined by using siRNA to knock down crucial components of the NXF1/TAP pathway, 
or chemical inhibitors such as importazole which inhibits nuclear import pathways. An 
alternative means of reducing nucleocytoplasmic transport could be to use dominant negative 
Ran proteins (Kurisaki, Kurisaki et al. 2006). 
The central question related to our work is why does VACV require the cell nucleus at such a 
late stage in its morphogenesis? Does the virus require a nuclear protein to be transported to 
the viral factory to assist in virion maturation? Or does the virus need to transport a viral 
protein into the nucleus in order to modulate a cellular pathway? It is possible that VACV 
inhibits nucleocytoplasmic transport at early stages in the virus life cycle in order to prevent 
host antiviral mRNA transcripts being trafficked into the cytoplasm and translated. Other 
viruses are known to employ this immune-evasion mechanism. However, later in the viral life 
cycle the host protein production has been very effectively shut off by the virus, and it may 
therefore be able to release the suppression of nucleocytoplasmic transport and use nuclear 
factors to facilitate the maturation of virions.      
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